What is MaxCyte's deferred revenue?

MaxCyte (MXCT) reported deferred revenue of $3.27M in Q1 2026.

How has MaxCyte's deferred revenue changed year-over-year?

MaxCyte's deferred revenue decreased by 21.1% year-over-year, from $4.15M to $3.27M.

What is the long-term trend for MaxCyte's deferred revenue?

Over 5 years (2020 to 2025), MaxCyte's deferred revenue has grown at a -5.8% compound annual growth rate (CAGR), from $4.84M to $3.6M.

What does deferred revenue mean?

Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.

MaxCyte MXCT Deferred Revenue

Deferred Revenue at other companies

Thermo Fisher ScientificTMO

$2.93B+2.2%

Ginkgo BioworksDNA

$14.91M-55.7%

Rapid Micro BiosystemsRPID

$6.63M+8.9%

PDE

Pro-Dex, Inc.PDEX

$144K—

TEC

Bio-TechneTECH

$38.43M+19.1%

Bio-Rad LaboratoriesBIO

——

Segments

By product

See full

Assay And Other Service Revenue$645K—

Other financials

Income statement

See full

Revenue$9.7M-7.1%

Gross profit$8.1M-9.1%

Operating income-$6.2M+49.7%

Net income-$4.8M+53.7%

EPS (diluted)-$0.04+60.0%

Balance sheet

See full

Cash & equivalents$14.6M-37.8%

Total debt$17.5M-7.1%

Total equity$167.9M-15.8%

Total assets$194.5M-15.4%

Cash flow

See full

Operating cash flow-$8.2M+43.3%

CapEx$72.0K-89.0%

Free cash flow-$8.2M+45.3%

Valuation

See full

Market cap$130.15M-46.8%

Enterprise value$133.08M-46.3%

P/S4×-2.8×

Profitability

See full

Gross margin80.5%-0.4pp

Operating margin-141.8%+6.4pp

Net margin-121.2%+12.3pp

FCF margin-90.9%+3.7pp

Returns & leverage

See full

Return on equity-21.3%+2.0pp

Debt / equity0.1×0.0×

Current ratio12×-0.2×

Where this comes from

Reported directly by MaxCyte in its filing.

Tagged under the XBRL concept us-gaap:DeferredRevenueCurrent.

The official record: MaxCyte’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about MaxCyte's deferred revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is MaxCyte's deferred revenue?: MaxCyte (MXCT) reported deferred revenue of $3.27M in Q1 2026.
How has MaxCyte's deferred revenue changed year-over-year?: MaxCyte's deferred revenue decreased by 21.1% year-over-year, from $4.15M to $3.27M.
What is the long-term trend for MaxCyte's deferred revenue?: Over 5 years (2020 to 2025), MaxCyte's deferred revenue has grown at a -5.8% compound annual growth rate (CAGR), from $4.84M to $3.6M.
What does deferred revenue mean?: Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.